Opthea Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Fred Guerard

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	2yrs

Recent management updates

Recent updates

CEO

Fred Guerard (50 yo)

less than a year

Tenure

Dr. Frederic Guerard, Pharm. D. M.S. also known as Fred, is Chief Executive Officer of Opthea Limited from October 27, 2023. He has been Independent Director at Lenz Therapeutics, Inc. since 2021.He is a...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Megan Baldwin	Founder	no data	US$1.57m	0.029% $ 127.0k
Judith Robertson	Chief Commercial Officer	2.3yrs	US$856.83k	no data
Karen Adams	VP of Finance & Company Secretary	2.8yrs	US$507.60k	no data
Frederic Guerard	Chief Executive Officer	less than a year	no data	no data
Peter Lang	Chief Financial Officer	less than a year	no data	no data
Sarika Gulhar	Executive Director of Human Resources	1.3yrs	no data	no data
Michael Gerometta	Head of Chemistry	15.3yrs	US$197.04k	no data
Bruno Gagnon	Senior Vice President of Global Clinical Operations	1.6yrs	no data	no data
Kenneth Sall	Chief Medical Officer	less than a year	no data	no data
Fang Li	Senior Vice President of Regulatory Affairs	less than a year	no data	no data
Julie Clark	Senior Vice President of Clinical Development	less than a year	no data	no data
Arshad Khanani	Chief Medical Advisor	less than a year	no data	no data

0.8yrs

Average Tenure

51yo

Average Age

Experienced Management: OPT's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Megan Baldwin	Founder	no data	US$1.57m	0.029% $ 127.0k
Jeremy Levin	Chairperson	3.5yrs	US$425.47k	0.0047% $ 20.5k
Jason Slakter	Member of Clinical Advisory Board	no data	no data	no data
Quinton Oswald	Independence Non-Executive Director	2yrs	US$202.36k	no data
Julia Haller	Independent Non-Executive Director	2.8yrs	US$327.41k	no data
Lawrence Gozlan	Independent Non-Executive Director	3.8yrs	US$724.31k	0.28% $ 1.2m
Sujal Shah	Non-Executive Director	no data	no data	no data
Anshul Thakral	Non-Executive Director	less than a year	US$3.16k	no data
Charles Wykoff	Member of Clinical Advisory Board	no data	no data	no data
Susan Orr	Independent Non-Executive Director	2yrs	US$206.20k	no data
Tim Jackson	Member of Clinical Advisory Board	no data	no data	no data

2.0yrs

Average Tenure

60yo

Average Age

Experienced Board: OPT's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

Opthea Management

Management criteria checks 0/4

Key information

Recent management updates

Less than half of directors are independent

Opthea Limited Announces Board Changes

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Recent updates

Consensus revenue estimates decrease by 14%

Less than half of directors are independent

Consensus EPS estimates fall by 11%

Opthea Limited Announces Board Changes

Consensus revenue estimates fall by 94%

Consensus revenue estimates decrease by 14%, EPS upgraded

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Consensus revenue estimates decrease by 94%

Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Opthea Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 94%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 9.0% to AU$1.55

Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited Announces Executive Changes

Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board

Consensus revenue estimates increase by 12%

Consensus EPS estimates upgraded to US$0.25 loss

Consensus EPS estimates fall by 44%

First half 2023 earnings released: US$0.17 loss per share (vs US$0.11 loss in 1H 2022)

Consensus revenue estimates increase by 12%

Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology

Consensus forecasts updated

Independent Non-Executive Director exercised options to buy AU$173k worth of stock.

High number of new directors

Opthea Limited Appoints Timothy E. Morris as Chief Financial Officer

Opthea Limited, Annual General Meeting, Nov 16, 2022

Consensus forecasts updated

Full year 2022 earnings: EPS and revenues miss analyst expectations

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea Limited, Annual General Meeting, Sep 26, 2022

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?

High number of new directors

Opthea Limited Announces Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy Presented at ARVO 2022

High number of new directors

Opthea Limited Announces Board Appointments

Consensus forecasts updated

Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Announces Data for OPT-302 in Patients with PVC

We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely

This Is Why Opthea Limited's (ASX:OPT) CEO Compensation Looks Appropriate

Price target decreased to AU$2.95

Full year 2021 earnings released: US$0.14 loss per share (vs US$0.043 loss in FY 2020)

Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation

Opthea Limited Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada

High number of new directors

Opthea's OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration

Price target decreased to AU$4.24

Opthea Limited Treats First Patient in Phase 3 Trials of OPT-302

Independent Non-Executive Director exercised options to buy AU$1.1m worth of stock.

We Think Opthea (ASX:OPT) Can Afford To Drive Business Growth

Opthea Limited Finalizes Study Designs and Start-Up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.03 loss in 1H 2020)

New 90-day low: AU$1.75

New 90-day low: AU$1.81

Analysts update estimates

Price target lowered to AU$4.37

What Type Of Shareholders Make Up Opthea Limited's (ASX:OPT) Share Registry?

New 90-day low: AU$2.10

Price target raised to AU$17.93

New 90-day low: AU$2.27